Please login to the form below

Not currently logged in
Email:
Password:

tardive dyskinesia

This page shows the latest tardive dyskinesia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

Its KarXT molecule aims to avoid the safety issues that have given existing antipsychotic medicines a bad name, these include tardive dyskinesia, metabolic dysfunction, weight gain, glucose intolerance, sedation and others

Latest news

More from news
Approximately 7 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics